Gandjbakhch et al. 17 underscore the importance of this novel HCM subgroup with clinical studies in mutation carriers, utilizing echocardiographic and Doppler parameters. In the earliest days of molecular biology in HCM, a time period which now spans two decades, such family members were sporadically identified as part of specific pedigree studies and protocols performed in selected research laboratories in the USA, Europe, and Japan. However, more recently, molecular diagnosis has become much more available due to the evolution of commercial testing, currently available from four companies in the USA.
Since it is now generally conceded that the identification of specific mutations has little value in predicting prognosis in HCM patients, the primary role for such testing remains for the diagnosis of relatives in families with documented HCM, or possibly in probands for whom definitive diagnosis is ambiguous by standard clinical strategies, e.g. in distinguishing HCM from physiological 'athlete's heart'.
However, a complicating factor in this regard remains the substantial (and increasing) genetic heterogeneity attributable to HCM, now with .1000 mutations in 13 or more genes that encode proteins within and associated with the sarcomere, but nevertheless accounting for only 50% of the HCM disease spectrum. b-Myosin heavy chain (MYH7) and myosin-binding protein C (MYBPC3) genes are predominant and account for 80% of the genotyped patients. Furthermore, fully two-thirds of these mutations are 'private' (i.e. as yet reported in only one family), thereby limiting the prognostic weight that can be attributed to individual mutations, and giving rise to the possibility that many identified mutations are not truly disease causing. Indeed, the 'variants of unknown significance' issue is emerging as a significant limitation to the reporting of clinically relevant genetic testing data in HCM patients, requiring resolution by positive genetic testing in other family members, or by recognition that a specific mutation has previously been documented as pathogenic in other families. This is a relevant consideration for family members potentially designated as gene(+) phenotype(-).
Putting these considerations and concerns aside, it is obvious that we are nevertheless witnessing the identification of substantially increased numbers of preclinical mutation carriers, due largely to a greater accessibility to molecular diagnosis, and presumably this trend will only increase in the coming years.
However, while the genomics of HCM represent a powerful advance in diagnostics, it has also created a series of emerging clinical dilemmas. The natural history, risk of sudden death, general prognosis, and potential management strategies and decision-making related to mutation carriers is not only currently unresolved, but also essentially unknown given the youthful age of the affected relatives and the limited follow-up available in this subset-which requires substantial periods of longitudinal observation (probably encompassing decades). Also unknown is which (and how commonly) gene(+) phenotype (2) There has also been substantial interest in using non-invasive ECG, echocardiography, and Doppler parameters to identify abnormalities of LV myocardium in gene carriers preceding the appearance of hypertrophy, i.e. LV diastolic dysfunction, remodelling, or tissue characterization. 3,10 -16 Indeed, evidence that the non-hypertrophied LV muscle of gene(+) phenotype( -) family members may be electrically and functionally altered is evident in these studies which report abnormal ECG patterns in 50% 23 and diastolic dysfunction with varied sensitivity (44 -100%) and specificity (93 -100%) for predicting the affected genotype. 3, 10, 11 Gandjbakhch et al. 17 propose a novel approach to defining such abnormalities in mutation carriers with a combined echocardiographic and Doppler strategy that integrates tissue Doppler imaging (TDI), ventricular septal E/Ea ratio, the ventricular septum to LV free wall ratio, and also relative wall thickness. The authors report an 'echo/TDI' score which identified affected mutation carriers [i.e. with MYH7, MYBPC3, and troponin T (TNNT2) genes] with 67% sensitivity and 96% specificity. However, such non-invasive clinical approaches, such as 'echo/ TDI score', cannot be regarded as sufficiently diagnostic to supplant genetic testing. Furthermore, it is unknown whether such findings in mutation carriers predict the eventual development of LV wall thickening.
In conclusion, the expanding preclinical genotype(+) phenotype(2) HCM subgroup represents a major challenge to clinicians. Answers to the prevailing important questions concerning management decisions for such individuals will unavoidably require many years of careful assembly of data in large cohorts with longitudinal and substantial follow-up. In addition, studies such as that of Gandjbakhch et al., targeting the pathophysiology and clinical recognition of gene carriers, represent an important advance in this rapidly evolving area.
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